BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 15, 2008
 |  BioCentury  |  Product Development

Ambit's selectivity gambit

Ambit Biosciences Corp. is hoping to have the first FLT3 inhibitor that is sufficiently potent and selective to be used as a single agent in acute myelogenous leukemia. After seeing a good response rate early in a Phase I trial, the company modified the study to evaluate a continuous-dosing regimen of AC220 and hopes to jump straight into a pivotal study by the end of 1H09.

Ambit believes AC220's specificity for inhibiting FMS-like tyrosine kinase 3 (FLT3) is the key that allows it to be given as monotherapy in doses strong enough to produce durable responses in AML patients with FLT3 mutations.

Activating mutations in FLT3 are believed to play a role in increasing cell proliferation, leading to poor prognosis when compared to wild-type FLT3. Such mutations are present in about a third of AML patients.

Ambit is not the first company to target FLT3 inhibition. Cephalon Inc. and Novartis AG have begun Phase...

Read the full 780 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >